c-Met/HGFR
c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymalorigin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.
All Product Categories
-
c-Met/HGFR Inhibitors
(236)
View all products
-
c-Met/HGFR Agonist
(1)
View all products
-
c-Met/HGFR Activators
(3)
View all products
-
c-Met/HGFR Modulators
(2)
View all products
-
c-Met/HGFR Degraders
(11)
View all products
-
c-Met/HGFR Ligands
(4)
View all products
-
c-Met/HGFR Proteins
(48)
View all products
-
c-Met/HGFR Related Products (280)
Related Products (280)
-
Recombinant Proteins (48)
-
Antibodies (7)
-
KTN0073
0 ImagesCat. No.: HY-P992396KTN0073 is a high-affinity MET receptor tyrosine kinase inhibitor. KTN0073 can be used in studies related to non-small cell lung cancer and human cancers driven by HGF, MET amplification, or exon 14 mutation. KTN0073 binds to the Sema/PSI domain to block the HGF-MET interaction, and induces ubiquitination and degradation of oncogenic MET receptors via an HGF-independent pathway, thereby inhibiting MET-dependent signal transduction. KTN0073 exhibits significant antitumor activity in vivo, and its tumor suppressive activity is superior to that of the IgG1 subtype when grafted to the IgG2 constant region.
-
TR1801 Antibody
0 ImagesCat. No.: HY-P992477TR1801 Antibody is a c-Met/HGFR-targeting monoclonal antibody, and an antibody of ADC TR1801. TR1801 Antibody can be used for synthesis of ADCs.
-
MET/PDGFRA-IN-1
0 ImagesCat. No.: HY-149510CAS No.: 3125694-48-3MET/PDGFRA-IN-1 (compound 8c) is a MET and PDGFRA protein inhibitor (IC50: 36 μM for MET). MET/PDGFRA-IN-1 inhibits MET phosphorylation and induces cell apoptosis. MET/PDGFRA-IN-1 inhibits proliferation of MET-positive cells (IC50s: 15.3, 19.0, 22.0, 25.6, 21.0, 31.5 μM for AsPc-1, EBC-1, MKN-45, Mia-Paca-2, HT-29, K562 cells respectively).
-
MET M1250T Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70753Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET M1250T is a mutant of MET. MET M1250T Recombinant Human Active Protein Kinase is a recombinant MET M1250T protein that can be used to study MET M1250T-related functions.
-
KRC-00715
0 ImagesCat. No.: HY-164411CAS No.: 2079853-72-6KRC-00715 is an effective oral c-Met inhibitor with an IC50 of 9.0 nM, demonstrating high selectivity in gastric cancer cells. KRC-00715 specifically inhibits the growth of c-Met-highly expressed cell lines by inducing G1/S phase arrest, leading to a reduction in downstream signaling pathways, including Akt and Erk, as well as c-Met activity. KRC-00715, in the gastric cancer cell line Hs746, is characterized by an IC50 of 39 nM, and it selectively inhibits the proliferation of c-Met-highly expressed cell lines. KRC-00715 reduces tumor size in Hs746T xenograft mouse models.
-
MET F1200I Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70750Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET F1200I is a mutant of MET. MET F1200I Recombinant Human Active Protein Kinase is a recombinant MET F1200I protein that can be used to study MET F1200I-related functions.
-
PARP1/c-Met-IN-2
0 ImagesCat. No.: HY-178348PARP1/c-Met-IN-2 is a highly potent, orally active, PARP1 (IC50 = 21.8 nM) and c-Met (IC50 = 30.2 nM) dual inhibitor. PARP1/c-Met-IN-2 can elevate the expression level of γH2AX, cause DNA damage. PARP1/c-Met-IN-2 exhibits remarkable anti-tumor efficacy in the Olaparib (HY-10162)-resistant HCT116 (HCT116OR) xenograft models. PARP1/c-Met-IN-2 can be used for the study of Colon Cancer.
-
Tyrosine kinase-IN-4
0 ImagesCat. No.: HY-147612CAS No.: 765949-21-1Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein tyrosine kinase inhibitor.
-
c-Met-IN-9
0 ImagesCat. No.: HY-115937CAS No.: 2760326-29-0c-Met-IN-9, a 4-phenoxypyridine derivative, is a c-Met kinas inhibitor with an IC50 of 12 nM. c-Met-IN-9 induces cells apoptosis, and has antitumor activities.
-
c-Met ligand-1
0 ImagesCat. No.: HY-W425461CAS No.: 1103506-79-1
-
D6808
0 ImagesCat. No.: HY-151905CAS No.: 3029240-84-1D6808 is a highly selective and potent c‑Met inhibitor with an IC50 value of 2.9 nM. D6808 induces cell apoptosis and cell cycle arrest. D6808 can be used for the research of NSCLC and gastric cancers.
-
SOMCL-863
0 ImagesCat. No.: HY-116592CAS No.: 1452310-87-0SOMCL-863 is a selective and orally active c-Met inhibitor with antitumor activity in vitro and in vivo. SOMCL-863 can be utilized in cancer research.
-
X-376 (Standard)
0 ImagesX-376 (Standard) is the analytical standard of X-376. This product is intended for research and analytical applications. X-376 is a potent and highly specific ALK tyrosine kinase inhibitor (TKI) (IC50=0.61 nM). X-376 is a less potent inhibitor of MET (IC50=0.69 nM). X-376 displays potent anti-tumor activity.
-
Foretinib (Standard)
0 ImagesSynonyms: XL880 (Standard); GSK1363089 (Standard); GSK089 (Standard); EXEL-2880 (Standard)Foretinib (Standard) is the analytical standard of Foretinib. This product is intended for research and analytical applications. Foretinib is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
-
JNJ-38877618 (Standard)
0 ImagesCat. No.: HY-111050RCAS No.: 943540-74-7JNJ-38877618 (Standard) is the analytical standard of JNJ-38877618 (HY-111050). This product is intended for research and analytical applications. JNJ-38877618 is a potent, highly selective, orally bioavailable Met Kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively.
-
Amuvatinib (Standard)
0 ImagesSynonyms: MP470 (Standard); HPK 56 (Standard)Amuvatinib (Standard) is the analytical standard of Amuvatinib. This product is intended for research and analytical applications. Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity.
-
Ensartinib dihydrochloride (Standard)
0 ImagesCat. No.: HY-103714ARCAS No.: 2137030-98-7Synonyms: X-396 dihydrochloride (Standard)Ensartinib dihydrochloride (Standard) is the analytical standard of Ensartinib dihydrochloride (HY-103714A). This product is intended for research and analytical applications. Ensartinib dihydrochloride (X-396 dihydrochloride) is a BBB-permeable and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively.
-
RC-108 antibody
0 ImagesCat. No.: HY-P991177
-
BMS-794833 (Standard)
0 ImagesBMS-794833 (Standard) is the analytical standard of BMS-794833 (HY-10497). This product is intended for research and analytical applications. BMS-794833 is a VEGFR2 and Met inhibitor extracted from patent WO2009094417, compound example 1; has IC50s of 15 and 1.7 nM, respectively.
